Liu Qifa
- 3 Dobre • 1 opinie
- 33 lat doświadczenia
- Chiny, Pekin, Lu Daopei
Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.
She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.
Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.
Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.
She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.
Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.
Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.
He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.
He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.
Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.
He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.
Prof. Omay jest autorem ponad 65 artykułów naukowych z zakresu hematologii i specjalizuje się w przeszczepach komórek macierzystych. Szkolił się w prestiżowych instytucjach, w tym na Uniwersytecie Hacettepe i Uniwersytecie Ege.
Prof. Baytan specjalizuje się w leczeniu nowotworów dziecięcych i białaczek. Opublikował ponad 15 artykułów w międzynarodowych czasopismach.
Dr Omer Dogru specjalizuje się w hematologii i onkologii dziecięcej, posiadając bogate doświadczenie w haploidentycznych przeszczepach komórek macierzystych w Szpitalu Uniwersyteckim Biruni.
Profesor nadzwyczajny w dziedzinie hematologii z ponad 50 publikacjami – dr Eren specjalizuje się w haploidentycznym przeszczepianiu komórek macierzystych w Szpitalu Uniwersyteckim Biruni.
Dzięki ponad 40-letniemu doświadczeniu w hematologii i onkologii dziecięcej, dr Apak specjalizuje się w zaawansowanych metodach leczenia, takich jak przeszczep szpiku kostnego i terapia CAR T-cell.
Dr Prakash Pandit specjalizuje się w zaawansowanych technikach onkologii radiacyjnej w HCG Manavata Cancer Centre.
Specjalizuje się w transplantacji komórek macierzystych haploidentycznych w Liv Hospital Vadistanbul – wiodącym ośrodku złożonych procedur hematologicznych.
Docent Ali Hakan Kaya specjalizuje się w haploidentycznych przeszczepach komórek macierzystych w Szpitalu Uniwersyteckim Biruni, posiadając ponad dziesięcioletnie doświadczenie w hematologii.
Ponad 30 lat specjalizacji w hematologii i onkologii dziecięcej – Dr Lopez Ibor kieruje Oddziałem Hematologii i Onkologii Pediatrycznej w Grupie HM.
Dr Girish Badarkhe specjalizuje się w przeszczepach szpiku kostnego, posiadając ponad 13-letnie doświadczenie w leczeniu złożonych przypadków hematologicznych w HCG Manavata Cancer Centre.